As reported in this Letters to the Editor item, “Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis”, patients treated with Xeljanz (tofacitinib) for their rheumatoid arthritis (RA) may be at risk of neurological adverse events, such as Xeljanz-related peripheral neuropathy. That item about neurological Xeljanz adverse event reports was published in the March 2021 edition of JCR: Journal of Clinical Rheumatology.
According to the FDA, as of September 2021 some of the generally recognized Xeljanz side effects and Xeljanz adverse events are:
Myocardial Infarction (MI)
Strokes — Ischemic / due to a blood clot
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
We will continue to monitor the medical literature for developments regarding serious Xeljanz-related peripheral neuropathy and other Xeljanz adverse event reports.
At the present time, our law firm is investigating Xeljanz lawsuits filed against Pfizer, the pharmaceutical company responsible for Xeljanz, for patients with cases of Xeljanz causing heart problems such as heart attacks, strokes, pulmonary embolism (PE), and deep vein thrombosis (DVT), as well as Xeljanz causing lymphoma, lung cancer, and other cancers. Please feel free to contact us if we can help you or someone you know with a Xeljanz drug injury case.[View article in full at original source]